Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemigliptin/Dapagliflozin/Metformin FDC Bioequivalence Study
NCT07333742Phase 1Completed
- Sponsor
- LG Chem
- Start
- Sep 2025
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of gemigliptin, dapagliflozin and liquid metformin (Aspargo Labs) in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by LG Chem. Primary endpoints: Maximum Plasma Concentration at 72 hours and Area Under the Curve at 72 hours. Started Sep 2025; status: completed.
02
Drugs
gemigliptindapagliflozinliquid metformin (Aspargo Labs)
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07333742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07333742.